NCT06379217 2026-03-11NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.NovartisPhase 1 Active not recruiting31 enrolled